Manish Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Manish Kumar has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Kusum Yadav
Pathology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, IND
4 shared publicationsAkanksha Sharma
Pathology, Rama Medical College, Hospital and Research Centre, Hapur, IND
3 shared publicationsNidhi Gupta
Pathology, Dr. KNS Memorial Institute of Medical Sciences, Lucknow, IND
3 shared publicationsRashmi Kushwaha
Department of Pathology, King George’s Medical University, Lucknow, India
2 shared publicationsShalini Bhalla
Pathology, King George's Medical University, Lucknow, IND
2 shared publicationsSneha Chaudhary
Pathology, King George's Medical University, Lucknow, IND
2 shared publications
Latest Publications
- Open Access
- 22 December 2024
- Published by Springer Nature in Cureus
- Vol. 16 (12) , e76217
Evaluating the Incidence of Incidental Gallbladder Carcinoma in a Tertiary Care Centre: A Retrospective Analysis in North India
Background Incidental gallbladder carcinoma (IGBC) remains a significant clinical challenge, with its diagnosis often delayed due to the asymptomatic nature of the disease and its incidental discovery post-cholecystectomy. This study's aim is to calculate incidence in a high-risk, region-specific (North Indian) population and also to provide novel insights into clinical presentation as well as macroscopic and histopathological features of IGBC. Material and methods This retrospective observational study spanned four years (August 2013 to July 2016) and included a total of 3096 cases. Demographic, clinical, radiological, treatment and follow-up data were sourced from archived records. IGBC diagnoses were confirmed on formalin-fixed, paraffin-embedded tissue sections stained with hematoxylin and eosin (H&E). Results A total of 3,067 routine cholecystectomies were performed during this period, of which a total of 162 cases (18.93%) were diagnosed as gallbladder carcinoma (GBC) and 51 cases (1.74%) were identified as IGBC. The mean age was 49.8 years. Among the total IGBC cases, most patients underwent preoperative imaging of which eight cases (15.6%) showed findings on preoperative radiological evaluation suggestive of malignancy. Among these, five cases (9.8%) demonstrated subtle gallbladder wall thickening and three cases (5.8%) revealed suspicious small polypoidal lesions (less than 1 cm). Microscopy showed that majority of these tumours were well-differentiated adenocarcinomas (n=27; 52.94%), followed by moderately differentiated adenocarcinomas (n=17; 33.33%), mucinous adenocarcinomas (n=03; 5.88%), papillary adenocarcinomas (n=02; 3.92%), and neuroendocrine tumours (n=1; 1.96%). Staging revealed 26 (50.98%) cases as Stage IIA, 24 (47.0%) as Stage I, and one (1.9%) as Stage III. On follow-up, the median survival period was found to be 32 months. Conclusions Our study emphasizes the limitations of conventional imaging in detecting early-stage gallbladder cancer, and it advocated the critical importance of routine histopathological examination (HPE) of all gallbladder specimens. Additionally, our findings contribute to a growing body of evidence that suggests early-stage IGBC may offer improved survival outcomes if diagnosed timely and treated aggressively, prompting a re-evaluation of current diagnostic and management strategies.
- 22 December 2024
- Published by Springer Nature in Cureus
- Vol. 16 (12) , e76217
Open AccessEvaluating the Incidence of Incidental Gallbladder Carcinoma in a Tertiary Care Centre: A Retrospective Analysis in North India
Background Incidental gallbladder carcinoma (IGBC) remains a significant clinical challenge, with its diagnosis often delayed due to the asymptomatic nature of the disease and its incidental discovery post-cholecystectomy. This study's aim is to calculate incidence in a high-risk, region-specific (North Indian) population and also to provide novel insights into clinical presentation as well as macroscopic and histopathological features of IGBC. Material and methods This retrospective observational study spanned four years (August 2013 to July 2016) and included a total of 3096 cases. Demographic, clinical, radiological, treatment and follow-up data were sourced from archived records. IGBC diagnoses were confirmed on formalin-fixed, paraffin-embedded tissue sections stained with hematoxylin and eosin (H&E). Results A total of 3,067 routine cholecystectomies were performed during this period, of which a total of 162 cases (18.93%) were diagnosed as gallbladder carcinoma (GBC) and 51 cases (1.74%) were identified as IGBC. The mean age was 49.8 years. Among the total IGBC cases, most patients underwent preoperative imaging of which eight cases (15.6%) showed findings on preoperative radiological evaluation suggestive of malignancy. Among these, five cases (9.8%) demonstrated subtle gallbladder wall thickening and three cases (5.8%) revealed suspicious small polypoidal lesions (less than 1 cm). Microscopy showed that majority of these tumours were well-differentiated adenocarcinomas (n=27; 52.94%), followed by moderately differentiated adenocarcinomas (n=17; 33.33%), mucinous adenocarcinomas (n=03; 5.88%), papillary adenocarcinomas (n=02; 3.92%), and neuroendocrine tumours (n=1; 1.96%). Staging revealed 26 (50.98%) cases as Stage IIA, 24 (47.0%) as Stage I, and one (1.9%) as Stage III. On follow-up, the median survival period was found to be 32 months. Conclusions Our study emphasizes the limitations of conventional imaging in detecting early-stage gallbladder cancer, and it advocated the critical importance of routine histopathological examination (HPE) of all gallbladder specimens. Additionally, our findings contribute to a growing body of evidence that suggests early-stage IGBC may offer improved survival outcomes if diagnosed timely and treated aggressively, prompting a re-evaluation of current diagnostic and management strategies.
- Open Access
- 24 October 2024
- Published by Springer Nature in Cureus
- Vol. 16 (10)
Malignant Mixed Mullerian Tumor (Carcinosarcoma) in the Female Genital Tract: A Retrospective Study From a Single Center in North India
Background Carcinosarcoma (malignant mixed Mullerian tumor (MMT)) is a rare tumor of the uterus, even rarer in the ovary. Presenting symptoms are indistinguishable from high-grade uterine endometrium carcinoma. Histologically, tumors are biphasic, composed of both epithelial and mesenchymal (sarcomatous) components. The diagnosis of carcinosarcoma presents a challenge due to the need to exclude commonly occurring mimickers, necessitating the application of a broad panel of immunohistochemistry markers. Material and methods This retrospective descriptive study of malignant MMT was conducted over a three-year period (August 2021 to July 2024). A total of six (three ovarian and three uterine) cases diagnosed as malignant MMT were included based on morphology and confirmation by expressing positivity of cytokeratin (CK) and vimentin. All the demographic, clinical, and radiological data, treatment protocols, and survival data were obtained from the medical record department. Dako® (Agilent Diagnostics and Genomics Group, Santa Clara, California) antibodies were used for immunohistochemical (IHC) analysis with 1:100 dilutions. Results The mean age of presentation was 51.5 years (35-65 years). The primary tumor site was the uterus in four cases, bilateral ovaries in one case, and unilateral ovaries in one case. Metastasis was seen in two cases. Microscopically, the tumor was biphasic, displaying high-grade carcinomatous and sarcomatous components. Pan-CK was positive in the epithelial component of the tumor, while vimentin was positive in high-grade sarcomatous components. Epithelial membrane antigen (EMA) was positive in three cases, while myogenic was positive in heterologous rhabdomyosarcomatous component in one case. The mean ki-67 was approximately 52% (30%-80%). Conclusions Carcinosarcomas are highly aggressive tumors commonly occurring in elderly females. Uterine carcinosarcomas are rare, and ovarian carcinosarcomas are even rarer. Clinical and histological features resemble high-grade endometrial carcinoma, necessitating an extensive IHC panel to narrow down differentials and confirm the diagnosis. This study highlights the histological and IHC features and emphasizes that early diagnosis plays a crucial role in disease management.
- 24 October 2024
- Published by Springer Nature in Cureus
- Vol. 16 (10)
Open AccessMalignant Mixed Mullerian Tumor (Carcinosarcoma) in the Female Genital Tract: A Retrospective Study From a Single Center in North India
Background Carcinosarcoma (malignant mixed Mullerian tumor (MMT)) is a rare tumor of the uterus, even rarer in the ovary. Presenting symptoms are indistinguishable from high-grade uterine endometrium carcinoma. Histologically, tumors are biphasic, composed of both epithelial and mesenchymal (sarcomatous) components. The diagnosis of carcinosarcoma presents a challenge due to the need to exclude commonly occurring mimickers, necessitating the application of a broad panel of immunohistochemistry markers. Material and methods This retrospective descriptive study of malignant MMT was conducted over a three-year period (August 2021 to July 2024). A total of six (three ovarian and three uterine) cases diagnosed as malignant MMT were included based on morphology and confirmation by expressing positivity of cytokeratin (CK) and vimentin. All the demographic, clinical, and radiological data, treatment protocols, and survival data were obtained from the medical record department. Dako® (Agilent Diagnostics and Genomics Group, Santa Clara, California) antibodies were used for immunohistochemical (IHC) analysis with 1:100 dilutions. Results The mean age of presentation was 51.5 years (35-65 years). The primary tumor site was the uterus in four cases, bilateral ovaries in one case, and unilateral ovaries in one case. Metastasis was seen in two cases. Microscopically, the tumor was biphasic, displaying high-grade carcinomatous and sarcomatous components. Pan-CK was positive in the epithelial component of the tumor, while vimentin was positive in high-grade sarcomatous components. Epithelial membrane antigen (EMA) was positive in three cases, while myogenic was positive in heterologous rhabdomyosarcomatous component in one case. The mean ki-67 was approximately 52% (30%-80%). Conclusions Carcinosarcomas are highly aggressive tumors commonly occurring in elderly females. Uterine carcinosarcomas are rare, and ovarian carcinosarcomas are even rarer. Clinical and histological features resemble high-grade endometrial carcinoma, necessitating an extensive IHC panel to narrow down differentials and confirm the diagnosis. This study highlights the histological and IHC features and emphasizes that early diagnosis plays a crucial role in disease management.
- Open Access
- 15 September 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (18) , 5480
High-Density Lipoprotein-Associated Paraoxonase-1 (PON-1) and Scavenger Receptor Class B Type 1 (SRB-1) in Coronary Artery Disease: Correlation with Disease Severity
Background: Coronary artery disease (CAD) is the leading cause of death worldwide. High-Density lipoprotein (HDL) is a well-established marker associated with CAD. The current research goes beyond the conventional HDL-C measurement in previous studies and dives into the functional intricacies of HDL. By understanding how HDL works, rather than just how much of it exists, we can better tailor diagnostic and therapeutic strategies for CAD and related conditions. Hence, the current study quantifies the serum levels of two novel HDL-associated markers, Paraoxonase-1 (PON-1) and Scavenger Receptor Class B Type 1 (SRB-1), in CAD cases vs. controls. Methods: A total of 92 subjects, including 69 CAD and 23 healthy controls, were included, based on the prevalence of the disease. Further, based on the severity of the disease, CAD cases were subcategorized as CAD-I, -II, and -III. Serum PON-1 and SRB-1 levels were measured and compared between patient and control groups. Results: The levels of PON-1 and SRB-1 (32.6 ng/mL and 12.49 ng/mL) were significantly lower in CAD patients vs. the healthy control, at 60.36 ng/mL and 15.85 ng/mL, respectively (p < 0.000). A further intergroup comparison showed a statistically significant difference between the CAT-I and -III for PON-1 (p < 0.025), the CAT-I and -III, and CAT-II and -III for SRB-1 (p < 0.000). The receiver operating characteristics (ROC) curve showed cutoff values of 48.20 ng/mL and 14.90 ng/mL for PON-1 and SRB-1. Conclusions: The current study found that serum levels of HDL-associated PON-1 and SRB-1 are significantly lower in CAD cases, and were also inversely related to the increasing severity of coronary artery disease. This inference implies that serum PON-1 and SRB-1 could be used as non-invasive tools for the identification of coronary atherosclerosis and risk assessment in CAD cases.
- 15 September 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (18) , 5480
Open AccessHigh-Density Lipoprotein-Associated Paraoxonase-1 (PON-1) and Scavenger Receptor Class B Type 1 (SRB-1) in Coronary Artery Disease: Correlation with Disease Severity
Background: Coronary artery disease (CAD) is the leading cause of death worldwide. High-Density lipoprotein (HDL) is a well-established marker associated with CAD. The current research goes beyond the conventional HDL-C measurement in previous studies and dives into the functional intricacies of HDL. By understanding how HDL works, rather than just how much of it exists, we can better tailor diagnostic and therapeutic strategies for CAD and related conditions. Hence, the current study quantifies the serum levels of two novel HDL-associated markers, Paraoxonase-1 (PON-1) and Scavenger Receptor Class B Type 1 (SRB-1), in CAD cases vs. controls. Methods: A total of 92 subjects, including 69 CAD and 23 healthy controls, were included, based on the prevalence of the disease. Further, based on the severity of the disease, CAD cases were subcategorized as CAD-I, -II, and -III. Serum PON-1 and SRB-1 levels were measured and compared between patient and control groups. Results: The levels of PON-1 and SRB-1 (32.6 ng/mL and 12.49 ng/mL) were significantly lower in CAD patients vs. the healthy control, at 60.36 ng/mL and 15.85 ng/mL, respectively (p < 0.000). A further intergroup comparison showed a statistically significant difference between the CAT-I and -III for PON-1 (p < 0.025), the CAT-I and -III, and CAT-II and -III for SRB-1 (p < 0.000). The receiver operating characteristics (ROC) curve showed cutoff values of 48.20 ng/mL and 14.90 ng/mL for PON-1 and SRB-1. Conclusions: The current study found that serum levels of HDL-associated PON-1 and SRB-1 are significantly lower in CAD cases, and were also inversely related to the increasing severity of coronary artery disease. This inference implies that serum PON-1 and SRB-1 could be used as non-invasive tools for the identification of coronary atherosclerosis and risk assessment in CAD cases.
- Open Access
- 29 August 2024
- Published by Springer Nature in Cureus
- Vol. 16 (8) , e68152
Understanding the Puzzle of Primary Breast Lymphoma: An Experience in a Tertiary Care Center in North India
Background Breast carcinoma is the most common cause of death in women arising primarily from either epithelial or stromal components. Primary breast lymphoma (PBL) is a less common type of neoplasm arising from the lymphoid tissue and is classified as non-Hodgkin’s lymphoma (NHL). PBL is a rare tumor that accounts for less than 1% of total primary malignant neoplasms of the breast. The majority of PBLs are of B-cell origin; the most common histological type is diffuse large B-cell lymphoma (DLBCL) followed by follicular lymphoma (FL) and other T-cell and B-cell lymphomas. Material and methods We conducted this five-year retrospective descriptive PBL study from July 2019 to May 2024 at a tertiary care center in North India. We included 11 cases of diagnosed PBL based on morphology and confirmation by at least one lymphoid differentiation marker, that is, leukocyte common antigen (LCA). We retrieved paraffin-embedded blocks from the archive and conducted routine hematoxylin and eosin (H&E) staining and Leishman’s stain. We applied an extended immunohistochemistry (IHC) panel to confirm the microscopic findings. We used the Dako® (Agilent Diagnostics & Genomics Group) antibody with a dilution of 1:100. Results In this study, patients’ mean age was 46.8 years (32 to 84 years). Radiological findings indicated that the tumor was indistinguishable from carcinoma. Microscopic findings showed that cells were medium to large lymphoid cells displaying moderate pleomorphism, centrally placed nuclei, vesicular to coarsely clumped chromatin, and scant cytoplasm. IHC showed one case of T-cell origin (ALCL) and 10 of B-cell origin. Among the B-cell cases, four were DLBCL, four were high-grade NHL likely DLBCL and two were high-grade lymphoma. Conclusion Primary breast lymphoma is a rare tumor that closely resembles breast carcinoma clinically as well as radiologically. This study is an effort to highlight the importance of clinical, radiological, and histopathological parameters as well as immunohistochemical features in confirming diagnosis. We also emphasize a treatment protocol and survival outcome in hopes that this knowledge will provide an understanding of early diagnosis and proper management of disease.
- 29 August 2024
- Published by Springer Nature in Cureus
- Vol. 16 (8) , e68152
Open AccessUnderstanding the Puzzle of Primary Breast Lymphoma: An Experience in a Tertiary Care Center in North India
Background Breast carcinoma is the most common cause of death in women arising primarily from either epithelial or stromal components. Primary breast lymphoma (PBL) is a less common type of neoplasm arising from the lymphoid tissue and is classified as non-Hodgkin’s lymphoma (NHL). PBL is a rare tumor that accounts for less than 1% of total primary malignant neoplasms of the breast. The majority of PBLs are of B-cell origin; the most common histological type is diffuse large B-cell lymphoma (DLBCL) followed by follicular lymphoma (FL) and other T-cell and B-cell lymphomas. Material and methods We conducted this five-year retrospective descriptive PBL study from July 2019 to May 2024 at a tertiary care center in North India. We included 11 cases of diagnosed PBL based on morphology and confirmation by at least one lymphoid differentiation marker, that is, leukocyte common antigen (LCA). We retrieved paraffin-embedded blocks from the archive and conducted routine hematoxylin and eosin (H&E) staining and Leishman’s stain. We applied an extended immunohistochemistry (IHC) panel to confirm the microscopic findings. We used the Dako® (Agilent Diagnostics & Genomics Group) antibody with a dilution of 1:100. Results In this study, patients’ mean age was 46.8 years (32 to 84 years). Radiological findings indicated that the tumor was indistinguishable from carcinoma. Microscopic findings showed that cells were medium to large lymphoid cells displaying moderate pleomorphism, centrally placed nuclei, vesicular to coarsely clumped chromatin, and scant cytoplasm. IHC showed one case of T-cell origin (ALCL) and 10 of B-cell origin. Among the B-cell cases, four were DLBCL, four were high-grade NHL likely DLBCL and two were high-grade lymphoma. Conclusion Primary breast lymphoma is a rare tumor that closely resembles breast carcinoma clinically as well as radiologically. This study is an effort to highlight the importance of clinical, radiological, and histopathological parameters as well as immunohistochemical features in confirming diagnosis. We also emphasize a treatment protocol and survival outcome in hopes that this knowledge will provide an understanding of early diagnosis and proper management of disease.
- 1 August 2024
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
- Vol. 18 (8) , ER6-ER10
Cutaneous and Nodal Histiocytic Sarcoma: A Series of Five Cases
Histiocytic Sarcoma (HS) is an extremely rare haematolymphoid neoplasm that exhibits morphological and immunophenotypic features indicative of histiocytic differentiation. In most cases, it is misdiagnosed as Diffuse Large B-Cell Lymphoma (DLBCL) or anaplastic large cell lymphoma. HS is a diagnosis of exclusion, necessitating extensive immunophenotypic analysis to finalise the diagnosis. Hereby, authors present a case series of five cases diagnosed as HS based on histomorphology and an extensive Immunohistochemistry (IHC) panel. A total of five cases reported as HS over a five-year period (2018 to 2023) were diagnosed at the Department of Pathology. All demographic and clinical data, as well as treatment history, were collected from the patients and their family members. Paraffin-embedded blocks were retrieved from the archive, and routine Haematoxylin and Eosin (H&E) and special stains like Periodic Acid-Schiff (PAS) were performed. Microscopy revealed sheets of round to oval tumour cells with small round nuclei, inconspicuous nucleoli, and moderately microvacuolated cytoplasm. An extended IHC panel was applied to confirm the microscopic findings. All five cases exhibited intense immunoreactivity for Leukocyte Common Antigen (LCA) and showed strong positivity for the histiocytic marker CD68, while CD163 demonstrated variable cytoplasmic positivity. Dako R antibody at a dilution of 1:100 was used for the IHC analysis. This case series aims to highlight the importance of clinical, radiological, histological, and immunohistochemical properties of this rare neoplasm for early diagnosis and proper management.
- 1 August 2024
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
- Vol. 18 (8) , ER6-ER10
Cutaneous and Nodal Histiocytic Sarcoma: A Series of Five Cases
Histiocytic Sarcoma (HS) is an extremely rare haematolymphoid neoplasm that exhibits morphological and immunophenotypic features indicative of histiocytic differentiation. In most cases, it is misdiagnosed as Diffuse Large B-Cell Lymphoma (DLBCL) or anaplastic large cell lymphoma. HS is a diagnosis of exclusion, necessitating extensive immunophenotypic analysis to finalise the diagnosis. Hereby, authors present a case series of five cases diagnosed as HS based on histomorphology and an extensive Immunohistochemistry (IHC) panel. A total of five cases reported as HS over a five-year period (2018 to 2023) were diagnosed at the Department of Pathology. All demographic and clinical data, as well as treatment history, were collected from the patients and their family members. Paraffin-embedded blocks were retrieved from the archive, and routine Haematoxylin and Eosin (H&E) and special stains like Periodic Acid-Schiff (PAS) were performed. Microscopy revealed sheets of round to oval tumour cells with small round nuclei, inconspicuous nucleoli, and moderately microvacuolated cytoplasm. An extended IHC panel was applied to confirm the microscopic findings. All five cases exhibited intense immunoreactivity for Leukocyte Common Antigen (LCA) and showed strong positivity for the histiocytic marker CD68, while CD163 demonstrated variable cytoplasmic positivity. Dako R antibody at a dilution of 1:100 was used for the IHC analysis. This case series aims to highlight the importance of clinical, radiological, histological, and immunohistochemical properties of this rare neoplasm for early diagnosis and proper management.